Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
To the Editor: We have a number of concerns
about the clinical features of the CREATE-ECLA trial.1 First,
heparin used in coronary reperfusion therapy, such as the CREATE-ECLA patients
received, blocks the key GIK physiological effect of lowering free fatty acids.2 Unfortunately, CREATE-ECLA did not report free fatty
acid levels or look for this effect.
Cobb LA, Killip T, Lambrew CT, MacLeod BA, Rackley CE, Selker HP, Zalenski RJ. Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial. JAMA. 2005;293(21):2596-2598. doi:10.1001/jama.293.21.2597-a